SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2019 / Cilt: 22 - Sayı: 4

Subclinical atherosclerosis: A hidden threat for patients with ankylosing spondylitis

Wafa HAMDİ
Kaouther MAATALLAH
Pages
192–193
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the current study entitled “Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis” Anatol J Cardiol 2019; 22: 185-91, Hatipsoylu et al. (1), authors have failed to demonstrate the relationship between AS and atherosclerosis progression

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In the current study entitled “Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis” Anatol J Cardiol 2019; 22: 185-91, Hatipsoylu et al. (1), authors have failed to demonstrate the relationship between AS and atherosclerosis progression
📊
Key Findings & Data:In the current study entitled “Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis” Anatol J Cardiol 2019; 22: 185-91, Hatipsoylu et al. (1), authors have failed to demonstrate the relationship between AS and atherosclerosis progression
💡
Conclusion & Impact:In the current study entitled “Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis” Anatol J Cardiol 2019; 22: 185-91, Hatipsoylu et al. (1), authors have failed to demonstrate the relationship between AS and atherosclerosis progression
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

In the current study entitled “Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis” Anatol J Cardiol 2019; 22: 185-91, Hatipsoylu et al. (1), authors have failed to demonstrate the relationship between AS and atherosclerosis progression

🔖

Cite This Article

HAMDİ, W., MAATALLAH, K. (2019). Subclinical atherosclerosis: A hidden threat for patients with ankylosing spondylitis. The Anatolian Journal of Cardiology, Cilt: 22 - Sayı: 4, 192–193. https://ajindex.com/articles/367281

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hatipsoylu E, Şengül İ, Kaya T, Karatepe AG, Akçay S, Isayeva L, et al. Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis. Anatol J Cardiol 2019; 22: 185-91
  2. Perrault R, Omelchenko A, Taylor CG, Zahradka P. Establishing the interchangeability of arterial stiffness but not endothelial function parameters in healthy individuals. BMC Cardiovasc Disord 2019; 19: 190
  3. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and metaanalysis. Arthritis Care Res (Hoboken) 2011; 63: 557-63
  4. Bai R, Zhang Y, Liu W, Ma C, Chen X, Yang J, et al. The Relationship of Ankylosing Spondylitis and Subclinical Atherosclerosis: A Systemic Review and Meta-Analysis. Angiology 2019; 70: 492-500
  5. Yuan Y, Yang J, Zhang X, Han R, Chen M, Hu X, et al. Carotid IntimaMedia Thickness in Patients with Ankylosing Spondylitis: A Systematic Review and Updated Meta-Analysis. J Atheroscler Thromb 2019; 26: 260-71
  6. Lauper K, Gabay C. Cardiovascular risk in patients with rheumatoid arthritis. Semin Immunopathol 2017; 39: 447-59
  7. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotidatherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012; 25: 644-50
  8. Zardi EM, Pipita ME, Giorgi C, Lichinchi D, Zardi DM, Afeltra A. Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-a antagonists and healthy matched controls. Medicine (Baltimore) 2018; 97: e11250
  9. Hokstad I, Deyab G, Wang Fagerland M, Lyberg T, Hjeltnes G, Førre Ø, et al. Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study. PLoS One 2019; 14: e0220079
  10. Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, CarneroLópez B, Gómez-Acebo I, et al. Antitumour necrosis factor a treatment reduces retinol-binding protein 4 serum levels in nondiabetic ankylosing spondylitis patients. Ann Rheum Dis 2014; 73: 941-3
  11. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med 2013; 11: 117
  12. Pant S, Deshmukh A, Gurumurthy GS, Pothineni NV, Watts TE, Romeo F, et al. Inflammation and atherosclerosis--revisited. J Cardiovasc Pharmacol Ther 2014; 19: 170-8
  13. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the rol